1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. Prevention of venous thromboembolism. Chest. 2008;133:381S-453S

2. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events. J Bone Joint Surg [Br]. 2007;89-B:799-807.

1. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of Action Pharmacokinetics, Dosin Considerations, Monitoring, Efficacy and Satefy. Chest. 1992;102;337S-351S
2. Mueller RL, Scheidt S. History of Drugs for Thrombotic Disease. Circulation. 1994;89:432-449
3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lasen MR, Colwell CW et al. Prevention of Venous Thromboembolism. Chest. 2004;126(3 Suppl):338S-400S.
4. Turpie AG. Arterioscler Thromb Vasc Biol. 2007;27:1238-1247
5. Hirsh J, Levine MN, Low molecular weight heparin. Blood 1992;79:1-17
6. Nutescu EA. Antithrombotic Therapy for the Treatment of Venous Thromboembolism. Am J Manag Care. 2003;9(5 suppl):S103-S114.
7. Turpie AG, Bauer KA, Eriksson BI, MD, Lassen MR, Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery. Arch Intern Med. 2002;162:1833-1840
8. Erickson AK. Fondaparinux approved for deep-vein thrombosis.Pharmacy Today 2002 from www.medscape.com/viewarticle/436034
9. Pradaxa® Summary Product Characteristic, Boehringer Ingelheim Pharma
10. Xarelto® Summary of Product Characteristics, Bayer Schering Pharma AG
11. Eriksson Bl, J Bone Joint Surg BR. 2009; 91-B:636-644

1. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakker AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775

2. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786

1. Xarelto® Summary of Product Characteristics, Bayer Schering Pharma AG

2. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakker AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775

3. Kakkar AK, Brenner B, Dahl OE, Erikson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:29-37

4. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786

1. Diamantopoulos A, Forster F, Brosa M, Lees M, Gilmour L, Ashley D, et al. Cost Effectiveness of Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. ISPOR Nov 2008

2. Diamantopoulos A, Forster F, Lees M, Gilmour L, Ashley D, et al. Cost Effectiveness of Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK. ISPOR Nov 2008

1. Eriksson BI, Kakkar AK, Turpie AGG, Lassen MR, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surgery. 2009;91-B:636-644.

2. Turpie AGG, Lassen MR, Kakkar AK, et al. A pooled analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding. Poster presented at: the European Society of Cardiology (ESC); August 30-September 3, 2008; Munich, Germany. Abstract 86450.

3. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.

4. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.

5. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.

6. Turpie AGG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.

7. www.clinicaltrials.gov